Idiopathic inflammatory myopathy

13 trials 9 recruiting MedDRA PT
13 Registered trials
9 Recruiting
11 Unique sponsors
6 Unique IMPs
10 Commercial trials
Drug classes (ATC)
— ATC code not specified 12
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
FcRn antagonist 1 substance
CAR-T cell therapy 1 substance
Phase III: 1 Phase II/III: 1 Phase I/II: 4 Phase I: 3 Phase I (Other): 4

Filter these 13 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 13 trials

Phase III

1 trial
  • Pfizer Inc. Commercial
    DAZUKIBART
    2024-514648-10-00 6 countries 2025 n=23 Orphan
    Recruiting

Phase II/III

1 trial
  • Argenx Commercial
    EFGARTIGIMOD ALFA
    2024-512785-33-00 19 countries 2023 n=186
    Ended

Phase I/II

4 trials
  • Miltenyi Biomedicine GmbH Commercial
    AUTOLOGOUS T-CELLS TRANSDUCED WITH LENTIVIRAL VECTOR EXPRESSING A CHIMERIC ANTIGEN RECEPTOR DIRECTED AGAINST CD19
    2024-516819-24-00 1 country 2023 n=33
    Recruiting
  • Fraunhofer Institute For Translational Medicine And Pharmacology ITMP Academic
    CIZUTAMIG
    2025-522857-20-00 1 country 2026 n=12
    Recruiting
  • Universitaetsklinikum Heidelberg AöR Academic
    CNTY-101
    2024-519532-16-00 1 country 2025 n=12
    Recruiting
  • Universitaetsklinikum Heidelberg AöR Academic
    IDECABTAGENE VICLEUCEL
    2025-521530-28-00 1 country 2026 n=15 Orphan
    Recruiting

Phase I

3 trials
  • AstraZeneca AB Commercial
    IMP not specified
    2024-519015-34-00 4 countries 2025 n=32
    Recruiting
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    IMP not specified
    2024-517681-41-00 6 countries 2025 n=93
    Recruiting
  • CRISPR Therapeutics AG Commercial
    IMP not specified
    2024-518528-54-00 2 countries 2025 n=38
    Recruiting

Phase I (Other)

4 trials
  • Celgene Corp. Commercial
    IMP not specified
    2023-503823-24-01 5 countries 2024 n=126
    Halted
  • Century Therapeutics Inc. Commercial
    IMP not specified
    2024-518797-13-00 3 countries 2025 n=16
    Ended
  • Century Therapeutics Inc. Commercial
    IMP not specified
    2024-520222-11-00 3 countries 2026 n=15
    Recruiting
  • Ouro Medicines Limited Commercial
    IMP not specified
    2025-524100-29-00 1 country n=8
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Century Therapeutics Inc. Commercial 2 Phase I (Other) 1
Universitaetsklinikum Heidelberg AöR Academic 2 Phase I/II 2
AstraZeneca AB Commercial 1 Phase I 1
Bristol-Myers Squibb Services Unlimited Company Commercial 1 Phase I 1
CRISPR Therapeutics AG Commercial 1 Phase I 1
Argenx Commercial 1 Phase II/III 0
Celgene Corp. Commercial 1 Phase I (Other) 0
Ouro Medicines Limited Commercial 1 Phase I (Other) 0
Pfizer Inc. Commercial 1 Phase III 1
Miltenyi Biomedicine GmbH Commercial 1 Phase I/II 1
Fraunhofer Institute For Translational Medicine And Pharmacology ITMP Academic 1 Phase I/II 1
New trials by year
2023
2
2024
1
2025
6
2026
3
← All indication landscapes